PCK2 expression and activity level are critical for many cancer types: in tumor-initiating enriched prostate cancer cell clones, PCK2 was overexpressed, and this correlated with more aggressive tumors and lower survival rates (Zhao et al., 2017); in lung cancer cell lines and in non-small cell lung cancer samples, PCK2 expression and activity were enhanced under low-glucose conditions (Leithner et al., 2015); finally, it was reported that PCK2 is required for glucose-independent cancer cell proliferation and tumor growth in vivo (Vincent et al., 2015). Here, PCK2 is linked to neoplasm.